NFAT (the nuclear factor of activated T cells) upregulation has been linked to cellular transformation intrinsically, but it is unclear whether and how tissue cells with NFAT activation change the local environment for tumor initiation and progression. Direct evidence showing NFAT activation initiates primary tumor formation in vivo is also lacking. Using inducible transgenic mouse systems, we show that tumors form in a subset of, but not all, tissues with NFATc1 activation, indicating that NFAT oncogenic effects depend on cell types and tissue contexts. In NFATc1-induced skin and ovarian tumors, both cells with NFATc1 activation and neighboring cells without NFATc1 activation have significant upregulation of c-Myc and activation of Stat3. Besides known and suspected NFATc1 targets, such as Spp1 and Osm, we have revealed the early upregulation of a number of cytokines and cytokine receptors, as key molecular components of an inflammatory microenvironment that promotes both NFATc1 þ and NFATc1 À cells to participate in tumor formation. Cultured cells derived from NFATc1-induced tumors were able to establish a tumorigenic microenvironment, similar to that of the primary tumors, in an NFATc1-dependent manner in nude mice with T-cell deficiency, revealing an addiction of these tumors to NFATc1 activation and downplaying a role for T cells in the NFATc1-induced tumorigenic microenvironment. These findings collectively suggest that beyond the cell autonomous effects on the upregulation of oncogenic proteins, NFATc1 activation has non-cell autonomous effects through the establishment of a promitogenic microenvironment for tumor growth. This study provides direct evidence for the ability of NFATc1 in inducing primary tumor formation in vivo and supports targeting NFAT signaling in anti-tumor therapy.
INTRODUCTION
The NFAT (the nuclear factor of activated T cells) family of transcription factors is important for organ development and cellular homeostasis. The four NFATc (c1-c4) proteins reside in the cytoplasm in quiescent cells. When intracellular Ca 2 þ increases, the serine/threonine phosphatase calcineurin dephosphorylates the NFATc proteins and exposes the concealed nuclear localization signals, leading to their cytoplasm to nuclear translocation. In the nucleus, NFATc proteins complex with their partners to control the transcription of target genes. Nuclear import and activation of NFATc are opposed by phosphorylation of NFATc by GSK3 and other NFAT kinases. 1 However, when the serines targeted for phosphorylation by NFATc kinases and for dephosphorylation by calcineurin are changed to alanines, the modified NFAT proteins become constitutively nuclear and active. 2 Constitutively active NFATc1 was shown to induce transformation in preadipocytes. 3 NFATc1 activation, as evidenced by its nuclear presence and/or dephosphorylation state, has been observed in multiple types of human lymphomas. [4] [5] [6] The observation of ectopic activation of NFATc1 in pancreatic cancer and other cancer types suggests that NFAT activation may be used in a much wider set of tumors originated from cells with no normal expression of these proteins. [7] [8] [9] Although NFAT genes have been linked to multiple aspects of various tumor types, direct evidence showing NFAT activation initiates primary tumor formation in situ is lacking. In addition, the cellular function of NFAT signaling appears to be multifaceted and contextdependent. 10 Thus, the biological consequences of NFAT activation in different tissues may be very different and the mechanism by which NFAT affects tumorigenesis needs to be further investigated.
In this study, we generated a transgenic system in which NFATc1 activation can be controlled by the administration of doxycycline (Dox) in targeted tissues. We have discovered that NFATc1 activation induces tumor formation in situ by promoting local cytokine production to create an inflammatory microenvironment for cells with NFAT activation and their neighbors without NFAT activation to participate in tumor formation. Between two models with overlapping NFATc1 activation domains in the skin, only the one with NFATc1 expression in follicle stem/progenitor cells produced skin tumors, suggesting progenitor cell involvement. These and other findings reported here provide mechanistic insights into the tumorigenic effects of NFAT activation beyond its reported and suspected roles in direct transcriptional regulation of oncogenes.
RESULTS

Conditional activation of NFAT signaling results in tumors in specific sites
To study the role of NFAT signaling in urogenital organs, we created a transgenic model for inducible NFATc1 activation in cells targeted by the Hoxb7-Cre transgene 11, 12 that has known expression in the Wolffian duct, an embryonic structure providing progenitors for multiple urogenital organs ( Figure 1 ). In this system, Cre expression induces the removal of the transcriptional stop cassette in a ROSA rtTA allele and the production of rtTA (reverse tetracycline-controlled transactivator). When Dox is present, the Dox-rtTA complex binds to TetO of the TetONFATc1
Nuc transgene 2 to induce the transcription of NFATc1
Nuc (an activated form of NFATc1) ( Figure 1a ). We refer to mice carrying all three alleles (Hoxb7-Cre, ROSA rtTA and TetO-NFATc1 Nuc ) as mutants. Their littermates without the full set of three alleles cannot have NFATc1 activation even when treated with Dox and thus are regarded as controls. NFATc1
Nuc transcripts were detected in Dox-treated mutants, but not in controls (Figure 1b , E13.5 embryos, E: embryonic day). Dox-induced NFATc1 activation in Wolffian duct derivatives during embryogenesis results in congenital renal defects and reduced viability with incomplete penetrance in mutants (the renal defects will be described separately). We examined mutants that survived past weaning and found tumors in the urogenital systems of both genders and in the skin. In females, the tumors were in the ovary (Figures 1c  and d) while the male tumors were in the epididymis (data not shown). As epididymal tumors are very rare in humans, we chose to perform most of the subsequent experiments in ovarian and skin tumors. The ovarian tumors can be noticed as early as at 3 weeks of age. Hundred percentage of the female mutants (n ¼ 8) with Dox treatment since E0 (Embryonic day 0) developed tumors in the ovary. In addition to urogenital tumors, Dox-treated mutants developed occasional skin tumors among numerous precancerous lesions (Figures 1e and f) . As early as 1 week after Dox treatment at P21, small lumps appeared randomly in skin throughout the body in B98% of mutants (n ¼ 150). While most lumps stayed small, some of these apparent precancerous lesions continued to grow into tumors of substantial size under continuous Dox treatment. No control mice developed tumor at any sites.
NFATc1-induced tumors resemble ovarian sarcoma and skin squamous cell carcinoma in humans Cytologically, the ovarian tumors were comprised of spindleshaped cells that bear morphologic resemblance to undifferentiated mesenchymal cells (Figures 2a-f ). Many tumor cells showed mild-to-moderate atypia. Regions of coagulative tumor cell necrosis were also present (Figure 2b ). These tumors have scattered mitotic figures on hematoxylin and eosin-stained sections and high mitotic index as revealed by Ki67 immunostaining (Figure 2c ). The tumors showed destructive stromal invasion within the ovary and are associated with desmoplastic responses (Figure 2d ). The ovarian tumor cells strongly expressed mesenchymal markers, including a-smooth muscle actin (aSMA). There was insignificant expression of epithelial markers, such as cytokeratin 8 (Figures 2e and f) and E-cadherin (not shown), in the tumor. Taken together, the constellation of findings (mesenchymal cellular morphology and marker expression, high mitotic index, atypia, necrosis, desmoplasia, destructive stromal invasion and others) indicate that the ovarian tumors in these mice resemble malignant ovarian stromal tumors, 13 rather than benign ovarian fibroma, in humans. The ovarian tumors came as a surprise to us at first because there was no previous report of Hoxb7-Cre expression in the ovary. By crossing the Hoxb7-Cre transgene to the ROSA LacZ reporter mice, we found b-galactosidase activity, reflecting Cre expression, in the ovarian stroma containing the theca cells and other SMA þ stromal cells surrounding the ovarian follicles (Figures 2g and h and data not shown). These tumors were CD10 À , unlike some of the ovarian sarcomas with an endometrial Hoxb7-Cre expression, as reflected by b-galactosidase activity, was also detected in the skin, primarily in hair follicle cells (Figure 2i ). Histopathological analyses showed that the skin tumors diffusely invaded the dermis, the subcutaneous fat, and superficially into the subadjacent connective tissues and skeletal muscle (Figures 2k-m) . Geographic necrosis was present (arrowhead in Figure 2m ). These skin tumors have keratin pearls typical of human cutaneous squamous cell carcinoma (SCC), though vague rudimentary structures resembling skin adnexal structures were present (Figure 2l ). Similar to the ovarian tumors, these skin tumors were highly proliferative, as revealed by proliferating cell nuclear antigen (PCNA) staining (Figure 2n ). Many cells in the skin tumors expressed the epithelial marker E-cadherin (Figures 2o and  p) . Immunostaining with cytokeratin 5, a diagnostic marker for human SCC, further confirms the extensive presence of cells of epithelial origin in the tumor proper and its resemblance to human SCC (Figures 2q and r) . Although both the skin tumor and ovarian tumors showed histological features of malignancy and local invasion, no metastasis was observed in the mutants we have examined. As most mutants died from tumor burden and other comorbidities associated with NFATc1 activation in other tissues, it is currently unknown if any of the NFATc1-induced tumors will become metastatic if given sufficient time to progress in these mice. Although epididymal tumors were not extensively characterized in this study, Hoxb7-Cre expression in the epididymal epithelia, a Wolffian duct derivative, is well established, 11, 12 making these tumors most likely primary tumors induced by NFATc1 activation but not metastasis from other sites. Besides the three sites mentioned, tumors have not been found in other places with known Hoxb7-Cre expression, including neuronal tissues, renal collecting duct and ureteral epithelia. It appears that the oncogenic effects of NFATc1 activation are tissue/cell type-specific.
Tissue stem cells/progenitor cells participate in NFATc1-induced tumorigenesis In the skin, stem cells are known to reside in the hair follicle bulge and express CD34 and NFATc1 (( Figure 3a) and Horsley et al. 14 ) . Although NFATc1 expression appeared stronger in the CD34 could not distinguish between the endogenous NFATc1 and the transgene-derived NFATc1
Nuc proteins ( Figure 3b ). We thus examined the presence of the hemagglutinin (HA) tag fused to the NFATc1
Nuc protein that specifically recognizes the transgene product. HA signal was absent in the control without transgene expression ( Figure 3c Nuc relies on the detection of the transgene-specific HA tag (c-f ). There was no HA staining in the controls (c). In the mutants, most CD34 þ bulge stem cells were HA þ (d) and most NFATc1 þ cells in the hair follicles were HA þ (e, f ). NFATc1 and CD34 had extensive co-expression in the skin tumor but were both absent in cells surrounding the keratin pearls (g-i). Keratin-14 (K14) had extensive expression in the skin tumor and was present in the NFATc1 À , CD34 À cells surrounding the keratin pearls (j). CD44 þ , NFATc1 þ cells were present in hair follicle bulge (k). Many CD44 þ , NFATc1 þ cells were present in the skin tumor (l-n). Keratin pearls were exclusively CD44 þ , K14 þ (o). The Msx2-rtTA transgene was expressed in hair follicle matrix cells and hair shaft excluding the bulge where stem cells reside (p).The Msx2-rtTA-driven NFATc1 activation did not elicit tumorigenesis in the skin of mutants treated for 3 months since weaning (q, r). Immunostaining of human SCC sections shows the upregulation of NFATc1, compared with normal human skin sections (s, t). Inset in (t) shows the NFATc1 immunostaining in higher magnification. stem cells. Interestingly, while a high percentage of cells within the tumor expressed NFATc1, the cells surrounding the keratin pearls were exclusively devoid of NFATc1 and CD34 (Figure 3h ). Keratin-14, a known diagnostic marker for SCC, had extensive expression in NFATc1-induced SCC-like tumors, especially in cells surrounding the keratin pearls (Figure 3j) . A potential explanation for these data is that cells with NFATc1 activation did not participate in, but created the environment for, the formation of the keratin pearls and that multiple lineages of cells participated in the development of the SCC-like tumor with NFATc1 þ , CD34
þ cells expanding and acting as tumor-inducing cells for NFATc1 À cells at the same time. CD44 is expressed in multiple areas in normal skin, including bulge cells with NFATc1 expression (Figure 3k ). Co-expression of CD44 and NFATc1 was widely seen in mutant hair follicles and NFATc1-induced skin tumors (Figures 3l and m) , likely due to the expansion of the NFATc1 þ , CD44 þ hair follicle cells. However, CD44 was also present in cells within the keratin pearls that are NFATc1
À (Figures 3n and  o) . As CD44 has expression in other skin cells, such as keratinocytes (Yasaka et al. 15 and data not shown), NFATc1 is probably acting through cell autonomous effects on CD44 þ , NFATc1 þ cells for their expansion and through non-cell autonomous effects on CD44 þ , NFATc1
À cells (likely including keratinocytes) for their participation in the keratin pearls. In a separate model (Msx2-rtTA; TetO-NFATc1 Nuc ) where NFATc1
Nuc expression was Dox-induced in hair follicle matrix cells and hair shaft excluding the bulge, no skin tumor was observed (Figures 3p-r and Lin et al.
16
). As the key difference in the targeted cell population between the two models was the presence of NFATc1
Nuc in bulge stem cells in the Hoxb7-Cre; ROSA rtTA ; TetONFATc1
Nuc model, these results suggest that the abnormal activation of bulge stem cells could have an important role in the tumorigenesis of the SCC-like skin tumor.
To assess the prevalence of NFATc1 expression in the human SCC, we performed NFATc1 immunostaining on human SCC tissue arrays that consisted of human SCC specimens histopathologically confirmed by board-certified pathologists. Among 42 human SCC specimens investigated, we observed NFATc1-expressing cells in 24 (57% of the total) specimens (Figures 3s and t) . Twelve control samples analyzed show no NFATc1 expression beyond that in the hair follicle bulge (Figures 3s and t) . Thus, NFATc1 expression appears to be associated with a substantial percentage of the human SCCs we examined.
Activation of oncogenic proteins in NFATc1
À cells appears to result from non-cell autonomous mechanisms Although NFATc1 þ cells were extensively present in the NFATc1-induced tumors, not all NFATc1 þ cells were proliferating while many neighboring NFATc1 À cells were undergoing active proliferation. In the example of a skin tumor given in (Figures 4c and f) . Immunoblotting of lysates from normal skin and NFATc1-induced skin tumors showed that the level of phospho-Stat3 was greatly increased in NFATc1-induced skin tumors, though total Stat3 level was unchanged (Figure 4g ).
As NFATc1 is a transcription factor, the observed upregulation of c-Myc and Stat3 activation in NFATc1
À cells reflects indirect noncell autonomous effects of NFATc1 activation, likely initiated by the secretion of factors that have paracrine functions.
As NFATc proteins are known regulators of a number of cytokines and interleukin (IL)-6, in particular, has been shown to regulate Stat activation in tumors, 17 we sought to investigate the potential role of IL-6 and other cytokines in mediating the effects of NFATc1 activation. By reverse transcriptase PCR (RT-PCR), we showed that NFATc1 activation was accompanied by an increased IL-6 transcription in skin tumors (Figure 4h) . Areas of high levels of IL-6 are found in both skin and ovarian tumors (Figures 4I and j) . However, many areas with high IL-6 levels were populated primarily by NFATc1
À cells (Figures 4i and j) , suggesting that NFATc1 did not directly upregulate IL-6 transcription in these cells. Although some IL-6 may be secreted by infiltrating immune cells, high IL-6 levels can be seen in local-resident non-immune cells (Figures 4i-k and  data not shown) . Thus, NFATc1
þ cells appeared to signal their neighboring cells, likely through a paracrine action, to secrete IL-6. The upregulation of IL-6, and possibly other cytokines, provides an explanation to the observed widespread nuclear presence of Stat3 in these tumors (Figures 4c, f and g ). These findings suggest that a major effect of NFATc1 activation is the creation of a promitogenic local environment for both the tumor-initiating cells and their neighbors to contribute in tumor formation.
Allografts of NFATc1-induced tumors showed continuous dependency on NFATc1 for tumor progression and survival but not on T-cell functions
To directly test the essential role of NFATc1 activation in tumorigenesis and to examine the involvement of T cells in establishing the tumorigenic microenvironment, we studied the ability of the cells with NFATc1 activation to initiate tumorigenesis in athymic nude mice with severe T-cell deficiency. We first cultured the cells from an NFATc1-induced ovarian tumor (Figures  5a and b) . These cells were then injected to the rear flanks of nude mice. Tumor growth was detected at about 6 weeks after the injection in the Dox-treated recipient mice, but not in untreated ones (Figure 5c ). To further test the dependency of tumor growth and progression on NFATc1 activation, we stopped Dox treatment in a subgroup of these mice. Existing tumors started to shrink within days after Dox withdrawal (Figure 5d ). Such trend was reversed when NFATc1 activation was restored (Figures 5d and e) , indicating a continuous dependency of the tumors on NFATc1 activation, similar to that seen in cases of oncogene addiction. 18, 19 The tumor allografts retain some key characteristics of the primary tumors in many aspects, including the presence of a large number of NFATc1 þ cells (Figure 5f ). These allografts were also primarily composed of aSMA þ mesenchymal cells (Figure 5g ). Similar to the primary tumor, NFATc1 þ and NFATc1 À cells intermingled and were both actively proliferating (Figure 5h ). NFATc1 activation also stimulated Stat3 activation in both NFATc1 þ and NFATc1 À cells (Figure 5i ). While T cells are seen in the primary tumor, the grafts grown in nude mice are completely void of T cells (Figures 5j and  k) . As inflammatory cytokines, such as IL-6, are similarly upregulated in the grafts, the establishment of the inflammatory tumorigenic microenvironment is thus independent of T cells (Figures 4j and k, 5l , and data not shown) but likely dependent on local tissue-resident cells and other immune cells in this model.
Key molecular components of a proinflammatory microenvironment induced by NFATc1 activation
To capture the broader picture of molecular changes related to the oncogenic effects of NFATc1 activation and to further characterize the molecular components in the microenvironment of NFATc1-induced tumors, we performed whole-genome transcript profiling on three sets of samples: hair follicles and skin NFAT signaling and tumorigenesis P Tripathi et al collected from mutant and control mice treated with Dox for 2 days as well as NFATc1-induced skin tumors and normal skin from similarly treated littermate controls. In each sample sets, gene ontology) analysis for biological process indicated that most of the significant changes (fold change 42, Po0.05) were in genes related to cell proliferation, growth and metabolic processes, all of which are important for tumor initiation and progression (Figure 6a ). One hundred and fifty-six significantly changed genes were present across all three data sets (Figure 6b ). Many chemokines/cytokines-related genes were among the most significantly changed genes. These and other selected genes with high fold changes were subjected to RT-PCR analysis (Figure 6c ) with a subset further confirmed by quantitative PCR (Q-PCR) (Figure 6d ). All genes examined by Q-PCR showed increased expression at levels similar to those seen in microarray analyses.
Besides cytokines, a number of genes with the largest fold changes are related to acute inflammation, innate immune response and recruitment of lymphocytes (SAA3, SAA1, LCN2 and RETNLG), as well as to keratinization of the skin (SPRRs, EG433016, CHI3Ls and KRTs) (Supplementary Tables 1-3 ). These results are consistent with the histological findings of keratin pearls and the extensive presence of cells with keratin-14 expression in skin tumors. We found that the skin epidermis became hyperproliferative after 2 days of NFATc1 activation in mutants (Figures 6e and f) . Increased levels of proliferation, as evidenced by PCNA staining, was observed in the basal layer of the epidermis and in the outer root sheath cells of the hair follicle in the mutants 2 days after NFATc1 activation (Figures 6g and h ). As transgene expression was not detected in some of these cells, the hyperproliferation in these NFATc1
À cells again pointed to þ cells with nuclear Stat3 (53.14 ± 16.23%) than NFATc1 À cells with nuclear Stat3 (26.18 ± 9.42%, P ¼ 0.001, n ¼ 4) (c, f ). Western blot analysis of normal skin lysates from control mice and skin tumor from mutant mice was done by using an antibody against Stat3 (revealing the level of Stat3 proteins regardless of phosphorylation status) and an antibody against phospho-Stat3 (Tyr705, revealing the level of activated Stat3). The results showed activation of Stat3 specifically in NFATc1-induced skin tumors while the level of total Stat3 was unchanged (g). NFATc1 activation specifically upregulated IL-6 in the tumors as revealed by RT-PCR (h). IL-6 upregulation was also detected by immunostaining in skin (i) and ovarian tumors (j, k). CT, control; MT, mutant. þ (f ). The allografts in the nude mice resembled the original tumors in overall morphology, cellular composition (g), and the substantial levels of proliferation and Stat3 activation in NFATc1 À cells (h, i). By immunostaining with an anti-CD3 antibody, T cells were seen in primary ovarian tumor but not in the grafts grown in nude mice (j, k). Extensive IL-6 expression was noticed in the grafts in the nude mice (l).
non-cell autonomous effects of NFATc1 activation, most likely through alterations in microenvironment. By immunostaining, we have identified more extensive expression of IL-1b in skin from mutant mice compared with controls 2 days after NFATc1 activation ( Figures 6I and j) . Similar increases in oncostatin M levels were observed in mutant skin (Figures 6k and l) . The extensive presence of proinflammatory cytokines at very early stage of NFATc1 activation suggests that tissue-resident cells are capable of initiating the establishment of a promitogenic environment before significant infiltration of immune cells. The cytokine cascades within these local cells and subsequently in infiltrating immune cells may support the continuous evolution of the tumorigenic microenvironment and the progression of these tumors.
DISCUSSION
We have previously shown that calcineurin-NFAT signaling is involved in the development of multiple organ systems and in the cellular responses to extracellular environment. 1, [20] [21] [22] [23] As we continue these investigations, we serendipitously discovered that the activation of NFAT signaling in vivo can cause tumor formation in a subset of tissues, including the ovary and skin. Our studies on the primary and the transplanted tumors provide direct in vivo Figure 6 . Transcript profiling revealed that NFATc1 activation creates a proinflammatory microenvironment for tumor development. Gene ontology analysis revealed that the top categories for genes with significant transcriptional changes include cell proliferation, growth and metabolic processes (a). Venn diagram showed 156 genes commonly changed across all three sets (b). A number of the secretory factors were among the genes with the most significant changes. These and other significantly changed genes with potential links to NFAT signaling were subjected to further RT-PCR using skin from mutant and control mice treated with Dox for 48 h (c). CT, skin from control mice; MT, skin from mutant mice. Some of these genes were further validated by Q-PCR, which shows similar trend of expression change in mutant skin as suggested by microarray (d). hematoxylin and eosin and PCNA staining showed hyperproliferative mutant skin epidermis after 2 days of NFATc1 activation compared with control samples (e-h). Immunostaining showed more extensive expression of IL-1b and oncostatin M in skin from mutant mice compared with their littermate controls (i-l).
evidence that NFATc1 activation is sufficient for initiating tumorigenesis and is necessary for the progression of the tumors formed. At least in the systems we tested, NFATc1 can behave as a pleiotropic oncogene and tumors caused by its activation remain addicted to it.
Although the effects of NFATc1 activation may differ in different tissues, it is common for the NFATc1-induced tumors we studied, as well as the tumor allografts in the nude mice, that NFATc1 activation has effects beyond the cells where the activation occurs. Although c-Myc upregulation and Stat3 activation have been observed in some, but not all, NFATc1 þ cells in NFATc1-induced tumors, many NFATc1
À cells within the tumor also show upregulation of c-Myc and activation of Stat3 (Figures 4b, c, e and  f) . These findings suggest that the role of NFAT goes beyond cell autonomous effects in ways of direct regulation of c-Myc transcription and Stat3 activation. Combined with our analyses of the molecular and cellular components of the microenvironment in these tumors, a picture emerges that factors secreted by the NFATc1 þ cells initiate the establishment of an inflammatory and promitogenic tissue environment for both NFATc1 þ and NFATc1 À cells to proliferate and become part of the tumor. From our comparison of two models with or without hair follicle stem cell involvement, it appears that both the cell autonomous effects of NFATc1 activation and the alterations in tissue microenvironment may affect the stem cells/progenitor cells and their niches, leading to their participation in tumor formation.
One intriguing question is the nature of this secreted factor(s) that has the autocrine/paracrine function. This secreted factor is most likely a major initiating factor for, and a component of, the proinflammatory and promitogenic microenvironment. Our finding of elevated IL-6 transcript level in the tumors led to the suspicion of IL-6 fulfilling the role of such a secreted factor (Figure 4h ). However, further immunostaining of the tumor tissues, especially tissues from early-stage tumors, revealed distinct populations of cells expressing NFATc1 and IL-6, respectively (Figures 4i-k) . Thus, it appears that the upregulation of IL-6 is itself induced by this secreted factor(s). Transcript profiling suggested the presence of proinflammatory microenvironment in the very early stages after NFATc1 activation ( Figure 6 ). There is growing evidence supporting the role of proinflammatory cytokines in tumor progression. 24 Upregulation of a number of proinflammatory cytokines (Figures 4 and 6) , as a result of NFATc1 activation, can provide the mitogenic signals for both NFATc1 þ and NFATc1
À cells to proliferate. The ability of the NFATc1 þ cells to recruit neighboring NFATc1 À cells into the formation of tumors (beyond the vasculature) also makes the NFATc1 þ cells behave like tumor-initiating cells. Whether the cytokine genes are direct or indirect targets of NFATc1 is still under investigation. It is also possible that one of the cytokine genes is directly regulated by NFATc1 and its upregulation initiates a cascade of cytokine production, leading to the establishment of the proinflammatory and promitogenic environment.
NFATc1 is normally expressed in the CD34 þ hair follicle bulge stem cells. Inhibition of calcineurin/NFATc1 signaling has been shown to relieve the NFATc1-mediated repression of CDK4 and leads to stem cell activation and hair growth. 14 In the Hoxb7-Cre, ROSA rtTA , TetO-NFATc1
Nuc mutants, NFATc1 activation in hair follicle stem cells led to apparent expansion of the CD34 þ stem cells and the development of SCC-like skin tumor (Figures 3h and i) . The involvement of the stem cells in this model is further supported by the absence of skin tumors in the Msx2-rtTA, TetO-NFATc1 Nuc mutants where NFATc1 activation is in an overlapping set of skin cells excluding the bulge stem cells. These results seem contradictory to the finding by Horsley et al. on surface. However, it is well known that the calcineurin/NFAT pathway operates through establishing a balanced signaling with additional inputs from other pathways in different cellular contexts. 25, 26 CDK2 and CDK4 have been found to be dispensable for cell cycle progression, likely due to redundancy. 27, 28 In the tumor model, the key for stem cell expansion may be in the alteration of the stem cell microenvironment/niche. This is consistent with the finding that escape of hair follicle stem cells from growth-restrictive niches was a key process in woundinginduced tumorigenesis in skin. 29 The expansion of the CD34 þ stem cells can only partially explain the NFATc1-induced skin tumor formation that may involve a complex set of sequential or parallel processes, including the induction of other cell types to build structures like the keratin pearls and the possible differentiation of the CD34 þ stem cells into other cell types. Upregulation of NFATc1 expression has been reported previously in a number of human malignancies. 10 Our finding in human SCC specimens further expands the tumor types in which significant NFATc1 expression can be found in tumor cells and may contribute to the initiation and progression of these tumors. As our study indicates that NFATc1 activation has pleiotropic effects on the cells expressing it and on the neighboring cells in the context of alterations in a number of signaling pathways and in the microenvironment, inhibiting NFATc1 activation could be more effective than targeting one or more of the downstream pathways and factors in treating tumors with NFATc1 activation. The oncogene addiction revealed in the tumor allograft study further suggests that NFAT signaling may be an attractive target for anti-tumor therapy.
MATERIALS AND METHODS
Mouse (Mus musculus) strains and Dox treatment
All animal studies were approved by the Washington University Animal Studies Committee and have been conducted according to relevant NIH guidelines. The Hoxb7-Cre, ROSA rtTA , TetO-NFATc1
Nuc strains and the relevant genotyping methods were described previously. 2, 11, 23, 30 Nude mice (Foxn1nu, Harlan, Indianapolis, IN, USA) were used for tumor grafting at 6-8 weeks old. Dox was given through drinking water provided ad libitum at 2 mg/ml. Dox treatment was started at conception and at birth through water intake by the mother or at 21 days postnatally by the targeted mice.
Primary tumor cell culture
For primary tumor cell culture, ovarian tumors from 5-week-old Hoxb7-Cre; ROSA rtTA ; TetO-NFATc1
Nuc mice were harvested and cut into small pieces of o1 mm and cultured in Dulbecco's Modified Eagle's Medium-F12 (10% fetal bovine serum, 5% penicillin/streptomycin and 2 mg/ml Dox). Cells grew out of the tumor tissue chunks were fed with fresh media every 2-3 days, and subcultured before confluence. Cultured cells were tested for nuclear NFATc1 expression in the presence of Dox.
Tumor growth in nude mice
For allografts, aforementioned cultured tumor cells (o15 passages) were grown to 70-80% confluence, trypsinized and resuspended in phosphatebuffered saline. 3 Â 10 6 cells were injected subcutaneously into lower flanks of eight nude mice. Group 1 mice were untreated. Groups 2-4 were Dox-treated from the day of injection. Group 2 was killed on the 64th day. Dox was stopped for group 3 on the 76th day and restarted on the 99th day. Group 3 mice were finally killed on the 127th day. Dox was stopped for group 4 on the 99th day and the mice were killed on the 113th day. Tumor volume was determined using a previously described formula. 31 Histology, immunostaining and western blotting Tissues were fixed with 4% paraformaldehyde and embedded in paraffin. Seven micrometer sections were collected and stained with hematoxylin and eosin. Human tissue microarrays were obtained from Biomax (Biomax Inc, Rockville, MD, USA). X-Gal staining and immunostaining on cryostat sections were performed as described. 
